Intravitreal triamcinolone acetonide as primary treatment for diffuse diabetic macular edema: A prospective noncomparative interventional case series

European Journal of Ophthalmology

Volumn 16, Issue 1, 2006, Pages 129-133

  Nicolò, Massimo ^a,b   Nasciuti, F ^a   Lai, S ^a   Ghiglione, D ^a   Borgia, L ^c   Calabria, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Is Pre   (Italy)

Author keywords

Diabetic macular edema; Intravitreal triamcinolone

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FILTERING OPERATION; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA LUTEA; THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33645541934     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210601600120     Document Type: Article

References (31)

1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984; 91: 1-9.
2. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796-806.
3. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 1991; 98: 1594-602.
4. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-7.
5. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997; 13: 88-391.
6. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57-61.
7. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening and novel therapies. Diabetes Care 2003; 26: 2653-64.
8. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report number 2. Ophthalmology 1987; 94: 761-74.
9. Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990; 97: 503-10; discussion 510-1.
10. Han DP, Mieler WF, Burton TC. Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113: 513-21.
11. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979; 77: 171-80.
12. McCuen BW II, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 91: 785-8.
13. Kivilcim M, Peyman GA, El-Dessouky ES, Kazi AA, Cheema R, Hegazy H. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000; 31: 474-8.
14. Schleimer RP. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol 1993; 45 (Suppl): S3-7; discussion S43-4.
15. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroids reduces blood-retina barrier breakdown due to laser photocoagulation. Arch Ophthalmol 1992; 110: 155-9.
16. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138: 158-60.
17. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004; 88: 1131-6.
18. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111: 2044-9.
19. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218-24.
20. Ozkiris C, Evereklioglu K, Erkiliç N, Tamçelik E, Mirza. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004; 14: 543-9.
21. Bresnick GH. Diabetic macular edema: a review. Ophthalmology 1986; 93: 989-97.
22. Stratton IM, Kohner EM, Aldington SJ, et al. KPDS Group. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-63.
23. Jonas JB, Degenring R, Kreissig I, Akkoyun I. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004; 138: 1054-5.
24. Kreissig I, Degenring RF, Jonas J. Diffuse diabetic macular edema and intraocular pressure after intravitreal triamcinolone acetonide. Ophthalmologe 2004; 13: 153-7.
25. Jonas J B, Kreissig I, Degenring R. Treatment of edematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide. Klin Monatsbl Augenheilkd 2003; 220: 383.
26. Jonas J, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004; 122: 218-22.
27. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24-7.
28. Behar-Cohen F. Drug delivery to target the posterior segment of the eye. Med Sci (Paris) 2004; 20: 701-6.
29. Eljrrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ. Hydrogel probe for iontophoresis drug delivery to the eye. J Biomater Sci Polym Ed 2004; 15: 397-413.
30. Parkinson TM, Ferguson E, Febbraro S, Bakhtyari A, King M, Mundasad M. Tolerance of ocular iontophoresis in healthy volunteers. J Ocul Pharmacol Ther 2003; 19: 145-51.
31. Frucht-Pery J, Mechoulam H, Siganos CS, Ever-Hadani P, Shapiro M, Domb A. Iontophoresis-gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe. Exp Eye Res 2004; 78: 745-9.